SCHEMBL3372805

SCHEMBL3372805

C=CCC1(N)CCCCC1N

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.30
NOS1 P29475 1/20 0.30
NOS2 P35228 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30751 0.77 GAA (0.43) NOS3NOS1NOS2
SCHEMBL10607707 0.77 GAA (0.33)
SCHEMBL940875 0.76 THRB (0.30)
Hydrochloric Acid SCHEMBL2957423 0.76 GAA (0.42) NOS3NOS1NOS2
SCHEMBL1408287 0.72 KDM1A (0.31)
Hydrochloric Acid SCHEMBL28814652 0.71 KDM1A (0.32)
SCHEMBL2163195 0.71 GAA (0.37)
SCHEMBL14042739 0.70 MAOA (0.45)
SCHEMBL13246762 0.70 MAOA (0.45)
SCHEMBL4451124 0.69 KDM1A (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807479-B1 SHALE HYDRATION INHIBITION AGENT AND METHOD OF USE MI LLC (US) 2012-08-22 EP claimed
US-20100160681-A1 Chiral phosphoramides, chiral N-phosphonimines and methods for forming the same NOWA PHARMACEUTICALS, CO., LTD. (CN) 2010-06-24 US claimed
WO-2009000202-A1 CHIRAL PHOSPHORAMIDES, CHIRAL N-PHOSPHONIMINES AND METHODS FOR FORMING THE SAME NOWA PHARMACEUTICALS CO., LTD (CN) 2008-12-31 WO claimed
US-20100160681-A1 Chiral phosphoramides, chiral N-phosphonimines and methods for forming the same NOWA PHARMACEUTICALS, CO., LTD. (CN) 2010-06-24 US disclosed
EP-2125687-A1 PROCESS FOR THE SYNTHESIS OF ETHERS OF AROMATIC ACIDS E. I. Du Pont de Nemours and Company (US) 2009-12-02 EP disclosed
WO-2009000202-A1 CHIRAL PHOSPHORAMIDES, CHIRAL N-PHOSPHONIMINES AND METHODS FOR FORMING THE SAME NOWA PHARMACEUTICALS CO., LTD (CN) 2008-12-31 WO disclosed
WO-2008079218-A1 PROCESS FOR THE SYNTHESIS OF ETHERS OF AROMATIC ACIDS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2008-07-03 WO disclosed
EP-0244778-B1 MONO-TERTIARY-ALKYLATED TOLUENEDIISO-CYANATES AND DERIVATIVES AIR PRODUCTS AND CHEMICALS, INC. (US) 1991-10-16 EP disclosed
EP-0244778-A1 Mono-tertiary-alkylated toluenediiso-cyanates and derivatives AIR PRODUCTS AND CHEMICALS, INC. (US) 1987-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160681-A1 Chiral phosphoramides, chiral N-phosphonimines and methods for forming the same PHOSPHO1, PNP, CDK2 NOS3 2893/4885NOS1 2053/4885NOS2 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.